Prevalence and patterns of antidepressant switching amongst primary care patients in the UK

Mars, Becky
Heron, Jon
Gunnell, David
Martin, Richard M
Thomas, Kyla H
Kessler, David

School of Social and Community Medicine, University of Bristol, Bristol, UK

Becky Mars, Senior Research Associate in Epidemiology, Centre for Academic Mental Health, School of Social and Community Medicine, University of Bristol, Oakfield House, Bristol, BS8 2BN, UK. Email: [email protected]

Journal of Psychopharmacology 31(5):p 553-560, May 2017. | DOI: 10.1177/0269881117693748

Objective:

Non-response to antidepressant treatment is a substantial problem in primary care, and many patients with depression require additional second-line treatments. This study aimed to examine the prevalence and patterns of antidepressant switching in the UK, and identify associated demographic and clinical factors.

Method:

Cohort analysis of antidepressant prescribing data from the Clinical Practice Research Datalink, a large, anonymised UK primary care database. The sample included 262,844 patients who initiated antidepressant therapy between 1 January 2005 and 31 June 2011.

Results:

9.3% of patients switched to a different antidepressant product, with most switches (60%) occurring within 8 weeks of the index date. The proportion switching was similar for selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants and other antidepressants (9.3%, 9.8% and 9.2%, respectively). Most switches were to an SSRI (64.5%), and this was the preferred option regardless of initial antidepressant class. Factors predictive of switching included male gender, age, and history of self-harm and psychiatric illness.

Conclusion:

Over one in every 11 patients who initiates antidepressant therapy will switch medication, suggesting that initial antidepressant treatment has been unsatisfactory. Evidence to guide choice of second-line treatment for individual patients is currently limited. Additional research comparing different pharmacological and psychological second-line treatment strategies is required in order to inform guidelines and improve patient outcomes.